Silvia Vannuccini, Francesco La Torre, Federico Toscano, Anna Rosa Speciale, Milo Giani, Dilruba Tureli, Virginia Manzi, Angela Gallone, Felice Petraglia
{"title":"Medical treatment for adenomyosis: long term use of progestins.","authors":"Silvia Vannuccini, Francesco La Torre, Federico Toscano, Anna Rosa Speciale, Milo Giani, Dilruba Tureli, Virginia Manzi, Angela Gallone, Felice Petraglia","doi":"10.1080/09513590.2025.2511329","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Adenomyosis is a uterine disorder causing menstruation-related symptoms such as dysmenorrhea, heavy menstrual bleeding (HMB) and dyspareunia. A long-term management of the disease is required. Hormonal drugs are the most used, including a variety of progestins, even though few data are available on their long-term use in adenomyosis.</p><p><strong>Objective: </strong>To evaluate the long-term efficacy of different progestins, including progestin-only pills (POP), for the management of adenomyosis-related symptoms.</p><p><strong>Methods: </strong>A total of 140 patients (18-45 years) with adenomyosis were treated with progestins for at least three years. The treatment groups included dienogest (2 mg, <i>n</i> = 71), levonorgestrel-releasing intrauterine device (52 mg, <i>n</i> = 25), desogestrel (75 mcg, <i>n</i> = 20), and drospirenone (4 mg, <i>n</i> = 24). Symptoms were assessed using the Visual Analogue Scale (VAS) for pain and the Pictorial Blood Assessment Chart (PBAC) method for bleeding.</p><p><strong>Results: </strong>Dienogest significantly reduced dysmenorrhea, dyspareunia, and HMB, with efficacy maintained over three years in most patients. However, after the first year 49% of patients required a switch to other treatments due to side effects or contraception need. The levonorgestrel-releasing intrauterine device also effectively managed HMB and pain, with 15% of patients switching treatment due to side effects. Both drospirenone and desogestrel improved HMB and dysmenorrhea, but desogestrel had a higher discontinuation rate due to reduced long-term efficacy. Norethisterone acetate was used as a second-line treatment in cases of intolerance or inadequate response.</p><p><strong>Conclusion: </strong>Progestins are effective for the long-term management of adenomyosis symptoms. The flexibility in switching between different progestins or routes of administration may help in optimizing outcomes.</p>","PeriodicalId":12865,"journal":{"name":"Gynecological Endocrinology","volume":"41 1","pages":"2511329"},"PeriodicalIF":2.0000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecological Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/09513590.2025.2511329","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/27 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Adenomyosis is a uterine disorder causing menstruation-related symptoms such as dysmenorrhea, heavy menstrual bleeding (HMB) and dyspareunia. A long-term management of the disease is required. Hormonal drugs are the most used, including a variety of progestins, even though few data are available on their long-term use in adenomyosis.
Objective: To evaluate the long-term efficacy of different progestins, including progestin-only pills (POP), for the management of adenomyosis-related symptoms.
Methods: A total of 140 patients (18-45 years) with adenomyosis were treated with progestins for at least three years. The treatment groups included dienogest (2 mg, n = 71), levonorgestrel-releasing intrauterine device (52 mg, n = 25), desogestrel (75 mcg, n = 20), and drospirenone (4 mg, n = 24). Symptoms were assessed using the Visual Analogue Scale (VAS) for pain and the Pictorial Blood Assessment Chart (PBAC) method for bleeding.
Results: Dienogest significantly reduced dysmenorrhea, dyspareunia, and HMB, with efficacy maintained over three years in most patients. However, after the first year 49% of patients required a switch to other treatments due to side effects or contraception need. The levonorgestrel-releasing intrauterine device also effectively managed HMB and pain, with 15% of patients switching treatment due to side effects. Both drospirenone and desogestrel improved HMB and dysmenorrhea, but desogestrel had a higher discontinuation rate due to reduced long-term efficacy. Norethisterone acetate was used as a second-line treatment in cases of intolerance or inadequate response.
Conclusion: Progestins are effective for the long-term management of adenomyosis symptoms. The flexibility in switching between different progestins or routes of administration may help in optimizing outcomes.
背景:子宫腺肌症是一种引起月经相关症状的子宫疾病,如痛经、大量月经出血(HMB)和性交困难。需要对这种疾病进行长期治疗。激素药物是最常用的,包括各种黄体酮,尽管很少有数据表明它们在bb0的长期使用。目的:评价不同黄体酮(包括纯黄体酮丸)治疗子宫腺肌病相关症状的远期疗效。方法:140例(18-45岁)子宫腺肌症患者接受孕激素治疗至少3年。治疗组包括地诺孕酮(2 mg, n = 71)、左炔诺孕酮释放宫内节育器(52 mg, n = 25)、地索孕酮(75 mg, n = 20)、屈螺酮(4 mg, n = 24)。采用视觉模拟评分法(VAS)评估疼痛症状,采用图像血液评估图(PBAC)评估出血症状。结果:Dienogest可显著减轻痛经、性交困难和HMB,大多数患者疗效维持3年以上。然而,在第一年之后,由于副作用或避孕需要,49%的患者需要切换到其他治疗方法。释放左炔诺孕酮的宫内节育器也有效地控制了HMB和疼痛,15%的患者由于副作用而改变了治疗。屈螺酮和地索孕酮均能改善HMB和痛经,但由于长期疗效降低,地索孕酮的停药率较高。在不耐受或反应不足的情况下,醋酸去甲睾酮被用作二线治疗。结论:孕激素对子宫腺肌症症状的长期治疗是有效的。在不同的黄体酮或给药途径之间切换的灵活性可能有助于优化结果。
期刊介绍:
Gynecological Endocrinology , the official journal of the International Society of Gynecological Endocrinology, covers all the experimental, clinical and therapeutic aspects of this ever more important discipline. It includes, amongst others, papers relating to the control and function of the different endocrine glands in females, the effects of reproductive events on the endocrine system, and the consequences of endocrine disorders on reproduction